Results 251 to 260 of about 205,631 (301)
Some of the next articles are maybe not open access.
Prostate-specific membrane antigen
The Prostate, 1997In an effort to discover new prostate-specific antigens (PSAs) to enhance our understanding of the functions and behavior of the prostate and the complex processes involved in prostate tumor progression, the structure and function of the PSM antigen has been elucidated.The PSM antigen was recognized using the 7E11-C5.3 monoclonal antibody, generated ...
W R, Fair, R S, Israeli, W D, Heston
openaire +3 more sources
Clinical Nuclear Medicine, 2020
Abstract A 64-year-old man with recently diagnosed prostate adenocarcinoma with a total prostate-specific antigen level of 3.32 ng/mL and Gleason score 4 (3 + 4) was referred for 68Ga–prostate-specific membrane antigen PET/CT scan for pretreatment staging.
Nitin, Gupta +2 more
openaire +2 more sources
Abstract A 64-year-old man with recently diagnosed prostate adenocarcinoma with a total prostate-specific antigen level of 3.32 ng/mL and Gleason score 4 (3 + 4) was referred for 68Ga–prostate-specific membrane antigen PET/CT scan for pretreatment staging.
Nitin, Gupta +2 more
openaire +2 more sources
Clinical Nuclear Medicine, 2018
Abstract 68Ga-PSMA-11 PET/CT was performed in a 74-year-old man because of biochemical recurrence of prostate cancer following radiation therapy of the prostate gland 24 months earlier. Besides focal nuclide accumulation in the prostate gland suggestive of local recurrence, PET scan revealed no further pathologic ...
Benjamin, Noto +4 more
openaire +2 more sources
Abstract 68Ga-PSMA-11 PET/CT was performed in a 74-year-old man because of biochemical recurrence of prostate cancer following radiation therapy of the prostate gland 24 months earlier. Besides focal nuclide accumulation in the prostate gland suggestive of local recurrence, PET scan revealed no further pathologic ...
Benjamin, Noto +4 more
openaire +2 more sources
Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors
Biophysical Reviews, 2022Prostate-specific membrane antigen (PSMA), also called glutamate carboxypeptidase II (GCP(II)), is a Zn-dependent metalloprotease that is known as a well prostate cancer indication and a potential targeting towards anti-cancer medicines and drug delivery.
Zahra Nikfarjam +3 more
openaire +2 more sources
Prostate-specific Membrane Antigen PET in Prostate Cancer
Radiology, 2021Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals are playing a large role at the time of initial staging and biochemical recurrence for localizing prostate cancer, as well as in other emerging clinical settings. PSMA PET has demonstrated increased detection rate compared with conventional imaging and has been shown to change ...
Courtney Lawhn-Heath +9 more
openaire +2 more sources
Prostate-specific membrane antigen theranostics
Current Opinion in Urology, 2018Prostate-specific membrane antigen (PSMA) theranostics offers a new approach for a personalized and targeted treatment for metastatic prostate cancer. Lutetium-177-labelled PSMA-ligands (Lu-PSMA) is a radionuclide therapy that is directed to PSMA expressing prostate cancer.
Justin, Ferdinandus +3 more
openaire +2 more sources
Prostate-specific membrane antigen in breast carcinoma
The Lancet, 1997Diamandis and Yu reported that prostate-specific antigen (PSA) is not specific for prostate cells since it is produced by some breast tumours and more occasionally by tumours from different sources, including lung, ovary, and endometrium. PSA is also present in nipple aspirate from non-lactating women and values are increased in some samples from ...
J A, Uría +4 more
openaire +2 more sources
Clinical Nuclear Medicine, 2018
Abstract We present here a case of metastatic adrenocortical carcinoma with bilateral lung nodules. The patient had been treated with mitotane therapy initially and then was later referred for chemotherapy. There was progression of disease noted on the 18F-FDG PET/CT.
Saurabh, Arora +7 more
openaire +2 more sources
Abstract We present here a case of metastatic adrenocortical carcinoma with bilateral lung nodules. The patient had been treated with mitotane therapy initially and then was later referred for chemotherapy. There was progression of disease noted on the 18F-FDG PET/CT.
Saurabh, Arora +7 more
openaire +2 more sources
The Prostate, 2003
AbstractBACKGROUNDCurrently prostate‐specific membrane antigen (PSMA) is showing promise both as an imaging and therapeutic target for occult prostate cancer metastases. First generation antibodies against PSMA are used for the FDA approved Prostascint™ monoclonal antibody scan and second generation antibodies are being developed for therapeutic ...
Denise S, O'Keefe +2 more
openaire +2 more sources
AbstractBACKGROUNDCurrently prostate‐specific membrane antigen (PSMA) is showing promise both as an imaging and therapeutic target for occult prostate cancer metastases. First generation antibodies against PSMA are used for the FDA approved Prostascint™ monoclonal antibody scan and second generation antibodies are being developed for therapeutic ...
Denise S, O'Keefe +2 more
openaire +2 more sources